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ABSTRACT 
The presence of RGD on nanoparticles allows the targeting of βl integrins at the apical surface of human M cells 
and the enhancement of an immune response after oral immunization. To check the hypothesis that non-peptidic 
ligands targeting intestinal M cells or APCs would be more efficient for oral immunization than RGD, novel 
non-peptidic and peptidic analogs (RGD peptidomimitic (RGDp), LDV derivative (LDVd) and LDV 
peptidomimetic (LDVp)) as well as mannose were grafted on the PEG chain of PCL-PEG and incorporated in 
PLGA-based nanoparticles. RGD and RGDp significantly increased the transport of nanoparticles across an in 
vitro model of human M cells as compared to enterocytes. RGD, LDVp, LDVd and mannose enhanced 
nanoparticle uptake by macrophages in vitro. The intraduodenal immunization with RGDp-, LDVd- or mannose-
labeled nanoparticles elicited a higher production of IgG antibodies than the intramuscular injection of free 
ovalbumin or intraduodenal administration of either non-targeted or RGD-nanoparticles. Targeted formulations 
were also able to induce a cellular immune response. In conclusion, the in vitro transport of nanoparticles, uptake 
by macrophages and the immune response were positively influenced by the presence of ligands at the surface of 




Most human vaccines currently available are licensed for non-mucosal administration via subcutaneous or 
intramuscular routes [1]. However, most pathogens gain access to their hosts via the mucosal surfaces. It would 
thus be beneficial to develop mucosal vaccines that would avoid pain and the risks of infection associated with 
injections and could make large-population immunization more feasible [2]. Moreover, the administration of an 
antigen at one mucosal site can lead to the generation of an immune response, not only locally but also at distant 
mucosal sites, a phenomenon referred to as the common mucosal immune system [3]. 
Several vaccines have been developed for oral administration. These include bacterial vaccines against cholera 
and typhoid fever and viral vaccines against polio and, recently, rotavirus infections. 
All these vaccines are based on live attenuated or inactivated organisms, which elicit both humoral and cellular 
immunity. However, their intrinsic instability makes them difficult to deliver and raises safety issues as a 
reversion to an invasive state may occur [4,5]. Killed or inactivated whole organism vaccines generate a weaker 
immune response and require multiple doses [6]. Modern vaccinology focuses on a new generation of vaccines 
composed of purified sub-units that are, in many cases, protein or peptide antigens. However, these antigens are 
poorly absorbed when administered orally, mainly due to their low mucosal permeability and their lack of 
stability in the gastro-intestinal environment. Their immunogenicity is considerably lower than that of traditional 
vaccines [7]. To overcome these problems, their association with adjuvants that act as delivery systems, such as 
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polymeric particles and/or modulators of the immune response such as cholera toxin B, have been widely 
investigated [4,8]. The use of polymeric nanoparticles for the delivery of complex antigens, a combination of 
antigens, and genetic vaccines makes them one of the most promising strategies for oral vaccination [2,8]. 
Polymeric carriers protect antigens against degradation and inactivation in the harsh gastro-intestinal 
environment [7] and have the ability to enhance their transmucosal transport [8]. Besides all of these advantages, 
the lack of efficacy of these particulate systems to induce an immune response by the oral route has been 
frequently reported, possibly a consequence of poor particle uptake, and up to now none of them has reached the 
market. To enhance the efficacy of orally delivered antigen-loaded particles, methods increasing their uptake and 
their transcytosis by M cells seem particularly attractive [8]. M cells are specialized epithelial cells, located in 
the follicle-associated epithelium (FAE) of Peyer's patches [9]. They have high transcytotic capabilities and are 
able to transport a broad range of materials, such as bacteria, viruses, antigens and particles from the intestinal 
lumen to the underlying lymphoid tissues [10,11]. The morphology of M cells promotes the interaction of these 
materials with their apical membrane. Moreover, their basolateral membrane is deeply invaginated, forming a 
pocket hosting immune cells (antigen presenting cells (APC) and lymphocytes) [9]. As M cells are present at a 
very low density in the gut, specific targeting of M cells could enhance particle uptake by M cells [8]. Even if 
there is a lack of specific markers of human M cells, βl integrins have been shown to be overexpressed at the 
apical pole of human M cells [12,13]. We have demonstrated that grafting RGD that targets this integrin on the 
PEG chain of PLGA-based nanoparticles significantly increased their in vitro transport by M-like cells. 
Nevertheless, targeted-nanoparticles containing ovalbumin only slightly increased the IgG immune response 
after oral immunization [12]. We hypothesised that this was due to a partial degradation of the RGD peptide 
during its trafficking through the gastro-intestinal tract. 
The aim of this study was to encapsulate a model antigen in a polymer-based formulation in order to (i) target 
the apical surface of human M cells using non-peptidic ligands to avoid ligand degradation in the gastro-
intestinal tract and (ii) achieve a cellular and humoral immunization after oral delivery. Various ligands were 
grafted on the PEG chain of PCL-PEG and incorporated in PLGA-based nanoparticles. Four ligands targeting βl 
integrin were grafted: RGD as the peptidic reference, RGD peptidomimetic (RGDp), LDV derivative (LDVd) 
and LDV peptidomimetic (LDVp). This selection of ligands relies upon literature and in-house data. RGD 
molecules (oligopeptides, cyclic peptides and peptidomimetics) have been widely used in biomaterials science 
for stimulating cellular adhesion on surfaces via integrin receptors because such molecules mimic the cell 
attachment sites of various extracellular matrix proteins [14]. Although the RGD peptides target a lot of integrin 
sub-types, the tyrosine-based RGD peptidomimetics have been recently shown to interact selectively with the 
beta 3 and beta 1 sub-types [15-17]. On the other hand, LDV peptides are selective ligands of beta 1 integrin and 
their affinity could be improved by chemical modification with a diarylurea motif [18]. Similarly, LDV 
peptidomimetics featuring a diarylurea motif behaved as selective beta 1 ligands [19,20]. This integrin-targeting 
strategy was compared to the targeting of APC where mannose was selected as the ligand of macrophages and 
dendritic cells [21-23]. The influence of these different ligands on nanoparticle transcytosis through the intestinal 
epithelium or FAE and on their ability to induce an immune response after oral vaccination was evaluated in 
vitro and in vivo, respectively. 
 
2. Materials and methods 
2.1. Materials 
2.1.1. Chemicals and solvents 
Reagents and solvents were of analytical grade and purchased from Acros (Beerse, Belgium) and Sigma-
Aldrich-Fluka (Bornem, Belgium). Monomethoxypoly(ethylene glycol), triethylaluminum (1.9 M in toluene), 
N,N'-dicyclohexylcarbodiimide, dibutyltin dimethoxide, fluorescein, 4-(dimethylamino)pyridine, monometh-
oxypoly(ethylene glycol) (PEG), sodium cholate, tin(II) octanoate were purchased from Sigma-Aldrich-Fluka. ε-
Caprolactone (99%) was purchased from Sigma-Aldrich-Fluka and was dried over CaH2 and distilled before 
use. D,L-lactide and glycolide were obtained from PURAC (Gorinchem, NL) and were purified and dried before 
use. Methylene dichloride and acetonitrile were obtained from Acros. The radiolabeled L-[4,5-3H] lysine 
monohy-drochloride in aqueous solution was purchased form Amersham Biosciences (Little Chalfont, UK) with 
a specific activity of 89.0 Ci/mmol. 
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2.1.2. Cell culture 
Human colon carcinoma Caco-2 cell line (clone 1) was obtained from Dr. Maria Rescigno, University of Milano-
Bicocca (Milano, IT) and used from passage x + 12 to x + 30. The Human Burkitt's lymphoma Raji B line was 
purchased from American Type Culture Collection (Manassas, VA) and used from passage 102 to 110. The J774 
murine macrophage cell line was obtained from ECACC (Salisbury, UK). Dulbecco modified Eagle's minimal 
essential medium (DMEM, 25 mM glucose), RPMI 1640 medium, non-essential amino acids, L-glutamine and 
penicillin-streptomycin, Hank's balanced salt solution buffer (HBSS), phosphate buffer saline (PBS), trypsin 
(0.25%) with EDTA were purchased from Gibco™ Invitrogen Corporation (Carlsbad, CA). Heat-inactivated 
fetal calf serum was obtained from Hyclone (Perbio Sciences, Erembodegem, BE). Transwell® polycarbonate 
inserts (12 wells, pore diameter of 3 µm), cell culture plates 24 wells and 96 wells (flat bottom) and T-Flask for 
cell culture were purchased from Corning Costar (New York, NY). Anti-βl integrin antibody was obtained from 
USBiological (Massachusetts, US) and the Polyclonal rabbit anti-ovalbumin antibody from Abcam (abl221, 
Cambridge, UK). Albumin from bovine serum for molecular biology, Albumin from chicken egg white (Grade 
V, ≥98%), TWEEN® 20 and Triton® X-100 were purchased from Sigma-Aldrich-Fluka. Cytotoxicity Detection 
Kit (LDH) was obtained from Roche Diagnostic GmbH (Mannheim, DE). 
2.1.3. Immunizations and EL1SA 
Specific pathogen-free female Balb/C mice aged 6 weeks were purchased from JANVIER (Le Genest-Saint-Isle, 
FR). Ketamine (Ketalar) was obtained from Pfizer (BE), xylazine from Sigma-Aldrich-Fluka, Iodine solution 
(Iso-Betadine) from Meda (BE) and plates from Nunc-Immuno (Plate F96 MAXISORP, Thermo Fisher 
Scientific, Langenselbold, DE). Peroxidase-labeled rat anti-mouse immunoglobulin G was obtained from LO-
IMEX (Brussels, BE), Ficoll-Hypaque from Beckman coulter (ANALIS SA, Suarlée, BE), Mouse IFN-γ and IL-
4 DuoSet ELISA development kits from R&D Systems (Europe Ltd., Abingdon, UK). 
2.2. Polymers synthesis and characterization 
2.2.1. Polymer synthesis 
PLGA was prepared as previously described [24], by copolymerization of lactide and glycolide promoted by the 
dibutyltin dimethoxide as the catalyst [12]. To obtain the fluorescent polymer, fluorescein with a carboxylic acid 
function was prepared according to the method described by Cao et al. [25] and then was coupled to the MeO-
PLGA-OH using N,N'-dicyclohexylcarbodiimide as the coupling agent and 4-(dimethylamino)pyridine as the 
catalyst. PEG-b-PLGA was synthesized as previously described [26], by a conventional ring-opening 
polymerization of D,L-lactide and glycolide using PEG as the macroinitiator and stannous octanoate as the 
catalyst [27]. The PEG-PCL copolymer was also synthesized by ring-opening polymerization using 
triethylaluminum as the catalyst [28]. 
2.2.2. Polymer characterization 
1H NMR (400 MHz) spectra were recorded in CDC13 at 25 °C with a Brüker AM 400 apparatus (Labbay, 
Geldermalsen, NL). Size-exclusion chromatography (SEC) was carried out in THF at a flow rate of 1 mL/min at 
45 °C using an SFD S5200 auto-sampler liquid chromatograph (Chemie.DE, Berlin, DE) equipped with a SFD 
refractometer index detector 2000 and columns PL gel 5 µm (columns porosity: 102, 103, 104 and 105 Å). 
Polystyrene standards were used for calibration. The polymers used for the preparation of nanoparticles and 
PCL-PEG used for grafting are described in Table 1. 
2.3. Ligands 
The ligands grafted on the polymers described in Fig. 1 were the following: 
RGD: Gly-Arg-Gly-Asp-Ser (GRGDS) pentapeptide (97%) was purchased from NeoMPS (Polypeptide 
Laboratories  Group, Strasbourg, FR).  
RGDp: This Arg-Gly-Asp (RGD) peptidomimetic, based on the tyrosine template, was designed and synthesized 
according to protocols adapted from Biltresse et al. [15,16]. 
LDVd: This Leu-Asp-Val (LDV) tripeptide derivative, with a diaryl urea motif at N-terminus and a 
triethyleneglycol spacer-arm at C-terminus, was prepared by standard peptide synthesis in solution, according to 
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protocols adapted from Lin et al. [19]. 
LDVp: A LDV peptidomimetic was synthesized as described by Momtaz et al. [20]. 
Man: Mannose derivative, namely 2-aminoethyl-α-D-mannopyroside (MannOH-NH2), was synthesized as 
previously described [29]. 
2.4. Grafting of ligand on PCL-PEG by photografting 
PCL-PEG (13,200-5000) was solubilized in methylene dichloride or acetonitrile with O-succinimidyl 4-(p-
azidophenyl) butanoate as previously described [29] (0.6 mmol per gram of PCL-PEG). After solvent 
evaporation, the sample was irradiated at 254 nm in a quartz flask under an argon atmosphere for 20 min. After 
washing, the "activated" sample was immersed in a 1 mM solution of ligand in phosphate buffer (0.1 
M)/acetonitrile (1:1, v/v) at pH 8 and shaken for 24 h at 20 °C. Then the sample was washed and dried under a 
vacuum at 40 °C to constant weight. 
As previously described [29,30], the grafting rates were controlled with a tritiated probe (L-[4,5-3H] lysine 
monohydrochloride). 2946 nmol of covalently fixed probes per gram of copolymer were attained. The absolute 
amount of MannOH-NH2 contained in the products was determined by the phenol-sulphuric acid method and the 
amounts of 5425 ± 2 nmole of MannOH-NH2 were covalently grafted per gram of copolymer. 
 
Table 1. Polymers characteristics. 
Polymer Mn (SEC)a 
(g/mol) 
Mn (NMR)b (g/mol) Mnc PEG Mnd PCL Glycolide (mol%) Polydispersity 
index (PDI)e 
PLGA 22,000 - - - 25 1.8 
Fluorescent-
PLGA 
23,600 - - - 29 1.6 
PEG-b-PLGA 29,300 4600-16,500 (L)/4700 (G) - - 26 1.7 
PCL-b-PEG 18,200 - 5000 13,200 - 1.4 
a
 Polystyrene calibration. 
b
 Determined by NMR with the following formula: (L4.7/2)/(I52 + (I4.7/2)) * 100, where I47 is the signal intensity of the glycolide unit at 4.7 
ppm (CH2OCdbnd;O) and is the signal intensity of the lactide unit at 5.2 ppm (CH(CH3)OCdbnd;O). 
c
 Calculated from 1H NMR spectrum in CDCl3 at 25 °C by comparing the intensity of the terminal methyl group (CH2OCH3, 3.2 ppm) with 
the methylene protons (OCH2CH2O, 3.6 ppm). 
d
 Calculated from 1H NMR spectrum in CDCl3 at 25 °C by comparing the intensity of the methylene protons of PEG peak at 3.6 ppm, with 
the peak of the α-methylene protons of PCL at 4.05 ppm. 
e
 PDI = Mw/Mn, determined by SEC by polystyrene standard. 
 
2.5. Preparation and characterization of nanoparticles 
Nanoparticles were prepared by the "water-in-oil-in-water" solvent evaporation method as reported by Garinot et 
al. [12]. Briefly, 50 µL of a 75 mg ovalbumin/mL PBS was emulsified with 1 mL of methylene dichloride 
containing 50 mg of polymers (70% PLGA/15% PLGA-PEG/15% PCL-PEG with or without the ligand) with an 
ultrasonic processor (70 W, 15 s). The second emulsion was performed with 2 mL of 1% (w/v) sodium cholate 
aqueous solution. The double emulsion was then poured into 100 mL of a 0.3% sodium cholate aqueous solution 
and stirred at 37 °C for 45 min. The nanoparticle suspension was then washed twice in PBS by centrifugation at 
22,000g for 1 h. 
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Fig. 1. Ligands grafted on PCL-PEG. 
 
 
2.6.  Characterization of ovalbumin-loaded nanoparticles 
Nanoparticle size and zeta potential were determined in KCl 0.1 mM using the Zetasizer Nano Series Malvern 
[12] (Worcestershire, UK). 
Nanoparticles were centrifuged and supernatants collected. The loading efficiency and the loading capacity were 
determined by quantifying the unbound ovalbumin in the supernatant with the 
Micro BCA Protein assay Kit (Pierce PERBIO, Erembodegem, BE) [12]. Both loading efficacy (LE) and loading 
capacity (LC) were determined as follows: 
 
Nanoparticles were dissolved with 0.15 M NaOH containing 7.5% (w/v) SDS at 100 °C for 3 min [31]. SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions was used to evaluate the integrity of 
the ovalbumin after its encapsulation in polymeric nanoparticles. Dissolved nanoparticles were filtered through 1 
µm (Millipore low binding protein), concentrated on 30 KDa Amicon filters and loaded onto 11% (w/v) 
acrylamide gel. Proteins were visualized by silver staining and Western blot using a polyclonal rabbit anti-
ovalbumin antibody at a 1/3000 dilution. 
2.7. Nanoparticle transport across the in vitro M cells model 
2.7.1. In vitro model of the human FAE 
Caco-2 cells and Raji cells were grown as previously described [32,12]. The inverted in vitro model of the 
human FAE was obtained as described by des Rieux et al. [32]. Briefly, 3-5 days after Caco-2 cells seeding, the 
inserts were inverted. After 9-11 days, Raji cells were added in the basolateral compartments. The co-cultures 
were maintained for 5 days. Mono-cultures of Caco-2 cells were used as controls. Inserts were used in their 
original orientation for all the following in vitro experiments. Cell monolayer integrity, both in co- and mono-
cultures, was controlled by transepithelial electrical resistance (TEER) measurement using an EndohmTM tissue 
resistance chamber (Endohm-12, World Precision Instruments, Sarasota, FL) connected to a Millicell®-RES 
(Millipore, Billerica, MA) ohmmeter. 
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2.7.2.  Transport experiments 
Transport experiments were run in HBSS at 37 °C. The nanoparticle concentration was adjusted by diluting the 
stock solution (checked by FACS analysis, FACScan, Becton Dickinson, Erembodegem, BE) [32,12] in HBSS 
to a final concentration of 2.7 × 1010 nanoparticles per milliliter. After equilibration in HBSS at 37 °C, the apical 
medium of the cell monolayers was replaced by a nanoparticle suspension (400 µL) and inserts were incubated at 
37 °C over 90 min. For the inhibition study, cells were apically pre-incubated with an anti-βl integrin antibody at 
5 µg/mL in HBSS for 1 h at 37 °C, before adding nanoparticle suspensions at a final concentration of 2.7 × 1010 
nanoparticles/mL The inhibitor was present throughout the whole transport experiment (90 min at 37 °C). 
Basolateral solutions were then sampled and the number of transported nanoparticles was measured using a flow 
cytometer (FACScan) [32,12]. 
Results are expressed as apparent permeability coefficient (Papp) [33] (mean ± standard erroerent formr of the 
mean (SEM)). The absence of cytotoxicity of the diffulations was assessed by measuring the TEER values after 
each experiment and lactate dehydrogenase (LDH) activity released from the cytosol of damaged cells into the 
apical medium. 
The Papp is defined by the following formula: 
Papp = dQ/dtAC0 
where dQ/dt is the number of nanoparticles (np) present in the basal compartment as a function of time (s); A, the 
area of Transwell (cm2); and C0, the initial concentration of nanoparticles in apical compartment (np/mL). 
2.8.  Uptake of nanoparticles by macrophages 
Murine macrophages of the cell line J774 were employed to study the phagocytic uptake of PLGA-based 
nanoparticles. The J774 murine macrophage cell line was maintained as an adherent culture and was grown as a 
monolayer in a humidified incubator at 37 °C in 175 cm2 flasks (Corning Costar) containing RPMI 1640 medium 
supplemented with 10% (v/v) FCS, 1% (v/v) penicillin-streptomycin, 1% (v/v) L-glutamine and 1% (v/v) non-
essential amino acids. Cells were detached with a trypsin-EDTA solution and adjusted to the required 
concentration of viable cells. For nanoparticles uptake, macrophages were seeded in 24-well plate at 5.5 × 105 
cells/cm2 and left to adhere for 48 h at 37 °C in a humidified atmosphere of 5% (v/v) CO2. Before the uptake 
experiment, cells were washed twice with free RPMI 1640 and left for 30 min. Fluorescent nanoparticles were 
diluted in HBSS at final concentration of 3 × 108 nanoparticles/ml. Cells were incubated with 500 µl of the 
nanoparticle solution for 60 min at 37 °C. After incubation, cells were washed twice with cold HBSS, twice with 
cold HBSS containing 0.1% (w/v) BSA and 0.2% Tween 20, and twice with cold HBSS to remove non-
associated nanoparticles. After that these cells were incubated in a 0.1% (v/v) Triton® X-100 solution to release 
the nanoparticles that had been internalized by the macrophages. Nanoparticles were counted by FACS. Results 
are expressed as a percentage of the number of nanoparticles in the donor compartment. 
2.9.  Oral immunization with ovalbumin-loaded nanoparticles 
The mice were kept in hanging wire cages and allowed to feed and drink ad libitum. Mice were fasted the day 
before their immunization. Protocols were approved by the ethical committee for animal care of the faculty of 
medicine of Université catholique de Louvain. 
For the first oral vaccination study, five groups of eight mice were vaccinated by intragastric gavage with the 
following formulations containing ovalbumin: non-targeted PLGA nanoparticles, RGD-nanoparticles, LDVd-
nanoparticles, LDVp-nanoparticles and man-nanoparticles or free ovalbumin. As positive and negative controls, 
two groups of eight mice were also immunized by intramuscular injection with ovalbumin and PBS, 
respectively. 
For the second immunization study, six groups of eight mice were vaccinated by intraduodenal injection with the 
following formulations containing ovalbumin: non-targeted nanoparticles, RGD-nanoparticles, RGDp-
nanoparticles, LDVd-nanoparticles, LDVp-nanoparticles and man-nanoparticles. As positive and negative 
controls, one group of eight mice was immunized by intramuscular injection with ovalbumin and two groups of 
eight mice were immunized by intraduodenal injection with free ovalbumin and empty PLGA nanoparticles. For 
the intraduodenal administration, the animals were anesthetized by intraperitoneal administration with ketamine 
(50 mg/kg) and xylazine (15 mg/ kg). The abdomen was shaved and disinfected with iodine solution 
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immediately before surgery. The abdomen was opened by a small central incision, and meticulous care was 
taken to prevent blood loss. Formulations and control solutions were injected into the mouse duodenum 
immediately distal to the stomach. The injections were performed by insertion of a 0.5-in., 27-gauge needle 
oblique to the intestinal lumen. The incision in the peritoneum was sutured using 5-0 Polyglactin 910 (Vicryl, 
J&J, BE) and the skin using 6-0 Monofilament Nylon (Monosof, US Surgical, USA). The surgical procedure 
lasted approximately 15 min per animal. 
For all vaccination studies, mice were immunized on days 0 and 14 with 50 µg of ovalbumin free or loaded in 
particles in 100 µl each time. Blood samples were collected by retro-orbital puncture on days 12, 28 and 42. Sera 
isolated by centrifugation were stored at -20 °C before analysis. Ovalbumin-specific IgG levels were evaluated 
by ELISA [12]. Sera dilutions were made in ovalbumin-coated plates and the detection of anti-ovalbumin 
antibodies was carried out using peroxidase-labeled rat anti-mouse immunoglobulin G (total IgG). Mice were 
sacrificed 6 weeks post-immunization and spleens were removed aseptically. Splenocytes were purified on Fi-
coll-Hypaque density gradient centrifugation and were cultivated in a humidified incubator at 37 °C in 96-well 
plates containing RPMI 1640 medium, supplemented with 10% (v/v) FCS, 1% (v/v) penicillin-streptomycin, 1% 
(v/v) L-glutamine and 1% (v/v) nonessential amino-acids. Splenocytes were stimulated with free ovalbumin (10 
µg/well) in triplicates. After 48 h and 72 h, cell-free culture supernatants were harvested and analysed for IFN-γ 
and IL-4 production, respectively, by ELISA [12]. 
2.10. Statistics 
Particle transport across the co- and mono-culture cell monolayers was compared using ANOVA parametric tests 
(p<0.05) and immunization studies were analysed by Kruskal-Wallis non-parametric tests (p < 0.05). 
3. Results 
3.1. Physicochemical characterization of the nanoparticles 
Formulations were characterized in terms of size, zeta potential, loading efficiency and loading capacity of 
ovalbumin (Table 2). All nanoparticles had a mean size around 200 nm with a small polydispersity index. The 
zeta potentials of all formulations were slightly negative when measured in 0.1 mM KCl. 
The molecular weight and the integrity of encapsulated ovalbumin were checked by SDS-PAGE gel 
electrophoresis. Identical bands were observed for entrapped ovalbumin compared to native ovalbumin. 
Ovalbumin integrity was also detected by Western Blot (data not shown). Encapsulation of ovalbumin in 
nanoparticles did not seem to alter the integrity of the protein. 
 
Table 2. Physicochemical properties of the ovalbumin-loaded nanoparticles containing PLGA (70%)/PLGA-
PEG (15%)/PCL-PEG with or without grafted ligands (15%) (n = 3-5). 
 Non-targeted RGD RGDp LDVd LDVp Man 
Size (nm) 220±30 215±29 230 ± 25 222 ± 24 221±28 260±24 
Pdi 0.235 0.205 0.250 0.255 0.226 0.300 
Zeta potential (mV) -18±5 -18±6 -20±6 -15±5 -13±5 -22±6 
Loading efficiency (%) 15.7±0.5 19.7±2.6 17.6±3 16.2±3 18.4±2 18.2±3 
Loading capacity  
(µg OVA/mg polymer) 
11.8±0.4 14.8 ±2 13.2±2 12.2±3 14.8±1.5 13.7±2 
 
3.2. In vitro transport of targeted nanoparticles by enterocytes and FAE 
To evaluate the ability of the different ligands to target the apical surface of M cells, the transport by mono-
culture of Caco-2 cells (enterocytes) or co-cultures of Caco-2 cells and Raji cells (FAE) of nanoparticles 
displaying different targeting molecules was compared (Fig. 2A). Nanoparticles were incubated on the apical 
side of the mono- and co-cultures, at3 7 °C, over a period of 90 min. The average TEER values for each group 
were approximately 300 and 170 Ω/cm2 for mono- and co-cultures, respectively. The different nanoparticles did 
not influence the TEER during the transport experiment. For each formulation, the transport across co-cultures 
was significantly higher than that across mono-cultures (p < 0.05). As previously observed [12], the presence of 
PCL-PEG-GRGDS in the formulation significantly increased the transport of nanoparticles across the co-
cultures when compared to non-targeted nanoparticles. RGDp had the same effect on the nanoparticle transport 
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as RGD, increasing their transport by co-cultures three times, when compared to non-targeted nanoparticles. An 
inhibition of the transport of the RGD- and RGDp-nanoparticles by co-cultures was observed in the presence of 
the anti-integrin βl antibody in the apical compartment (p<0.05) (Fig. 2B). No significant difference between the 
uptakes of LDVd- and LDVp-nanoparticles was observed and the transport rates across mono- and co-cultures 
were comparable to non-targeted nanoparticle transport. Mannose-labeling of nanoparticles was able to increase 
their transport by both mono- and co-cultures, when compared with non-targeted nanoparticles. 
 
Fig. 2. Influence of ligand grafting on nanoparticle transport across mono- and co-cultures of Caco-2 cells. (A) 
Cell monolayers were incubated for 90 min at 37 °C with 2.7 x 1010 nanoparticles/ml of each formulation suspended in HBSS. (B) Cell 
monolayers were first apically pre-incubated with anti-βl integrin (inhibitor+) or without (inhibitor-) at 5 µg/ml in HBSS for 1 h at 37 °C, 
before adding nanoparticle suspension at a final concentration of 2.7 x 1010 nanoparticles/ml. The number of transported nanoparticles was 
evaluated by flow cytometry and is expressed as apparent permeability coefficient (Papp) as a mean ± standard error of the mean (SEM). ˙p < 
0.05: vs. NP, ˙˙p < 0.05: inhibitor vs. no inhibitor (n = 24). 
 
 
3.3. Uptake of nanoparticles by macrophages 
Their uptake by macrophages was also investigated in order to check whether the ligands grafted on the 
nanoparticles could affect their uptake by APCs. Quantification of nanoparticles uptake by J774 cells revealed 
that the presence of the ligand at the nanoparticle surface also influenced the uptake of nanoparticles by 
macrophages (Fig. 3). After 60 min. of incubation at 37 °C, LDVp and mannose-nanoparticles were three times 
more internalized by macrophages than non-targeted nanoparticles, confirming previous results where the uptake 
of man-nanoparticles by macrophages was 50% higher than that of the uncoated nanoparticles [34]. RGD and 
LDVd labeling of nanoparticles doubled nanoparticle internalization by macrophages when compared to non-
targeted nanoparticles, whereas RGDp labeling of nanoparticles did not influence the uptake of nanoparticles by 
these cells. 
3.4. Oral immunizations studies 
3.4.1. Intragastric administration of ovalbumin-loaded nanoparticles Mice were immunized twice with 50 µg of 
ovalbumin by gavage in order to evaluate the potential of the different formulations as oral vaccine delivery 
systems. The IgG concentration was determined by the measure of the optical density obtained after ELISA 
realized on sera sampled 6 weeks after priming. Results are expressed in function of the serum dilution factor 
(Fig. 4A). In addition, the optical densities at the 1/320 dilution of the serum of each mouse are displayed in Fig. 
4B. The number of non-responding mice was relatively high, and differences were not statistically significant 
due to the high variability within the groups. However, LDVd-nanoparticles increased the number of responding 
mice (three mice out of eight), inducing an increase of mean total IgG seric concentration. As expected, free 
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Fig. 3. Influence of ligand grafting on nanoparticle uptake by macrophages. Cell monolayers were incubated for 60 min 
at 37 °C with 500 µl of each formulation (3 x 108 nanoparticles/ml) suspended in HBSS. The relative affinity of the nanoparticles for the 
macrophages was evaluated by flow cytometry and is expressed as percentage of the donor solution as a mean ± standard error of the mean 
(SEM). Group b is significantly different from group a (p < 0.05) and group c is significantly different from group a (p < 0.001 ) (n = 24). 
 
 
Fig. 4. Influence of the ligand grafting at the nanoparticle surface on IgGtot concentration in serum of mice 
immunized by gavage with 2 x 50 µg of ovalbumin free or encapsulated (blood sampling 6 weeks after priming). 
(A) Mean of absorbance obtained after ELISA for each group in function of the serum dilution factor. (B) Mice individual absorbance 
obtained after ELISA at the 1/320 dilution of the serum (n = 8). 
 
 
3.4.2. Intraduodenal administration of ovalbumin-loaded nanoparticles 
To avoid a possible degradation of the nanoparticle or of their associated ligands in the stomach and to 
concentrate the formulation at the site of absorption, intraduodenal injection of the same amount of ovalbumin (2 
× 50 µg/mice) was used to perform a second immunization study (Fig. 5). All mice vaccinated with ovalbumin-
loaded nanoparticles showed a strong and significant enhancement in the IgG production against ovalbumin 
when compared to the immune response obtained after intragastric administration. A low immune response was 
observed in the group vaccinated with free ovalbumin, while no response was elicited by empty PLGA 
nanoparticles. Mice immunized with non-targeted, RGD- and LDVp-nanoparticles produced a systemic immune 
response, identical to the immune response elicited by the IM route. RGDp-, LDVd- and man-nanoparticles 
elicited the higher IgG response, although only RGDp-nanoparticles allowed induction of an immune response 
significantly different from the group immunized with free ovalbumin. The isotype of ovalbumin-specific serum 
IgG at day 42 is shown in Fig. 6. Intraduodenal administration of ovalbumin-loaded nanoparticles elicited 
predominantly IgG1 and some IgG2a antibodies. 
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Fig. 5. Influence of the ligand grafting at the nanoparticle surface on IgGtot concentration in serum of mice 
immunized by intraduodenal administration with 2 x 50 µg of ovalbumin free or encapsulated (blood sampling 6 
weeks after priming). (A) Mean of absorbance obtained after ELISA for each group in function of the serum dilution factor. (B) Mice 
individual absorbance obtained after ELISA at the 1/320 dilution of the serum (n = 6-10).˙p < 0.05. 
 
 
The cellular immune response was evaluated by measuring the IFN-γ production of splenocytes cultured in the 
presence of ovalbumin. A significant trend towards enhanced IFN-γ responses was observed in groups of mice 
immunized with ovalbumin loaded in nanoparticles compared with the response elicited by IM injection or by 
intraduodenal administration of free ovalbumin. Splenocytes from the groups immunized with LDVd- and man-
nanoparticles produced a very low amount of IFN-γ, while the others targeted formulations produced a high level 
of IFN-γ (Fig. 7). The IL-4 production by splenocytes remained very low (<30 pg/ml, data not shown). 
 
Fig. 6. Influence of the ligand grafting at the nanoparticle surface on IgG1 and IgG2a profile in serum of mice 
immunized by intraduodenal administration with 2 x 50 µg of ovalbumin free or encapsulated (blood sampling 6 
weeks after priming). Results are presented as a mean ± standard error of the mean (SEM) of absorbance obtained after ELISA for each 
group at the 1/160 dilution of the serum (n = 6-10). Immune response elicited by mice vaccinated with the empty nanoparticles was 
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Fig. 7. Influence of the ligand grafting at the nanoparticle surface on IFN-γ production by splenocytes of mice 
immunized by intraduodenal administration with 2 x 50 µg of ovalbumin free or encapsulated (splenocytes 




The aim of this study was to develop non-peptidic ligands targeting intestinal M cells or APCs for oral 
immunization. Hence, PCL-PEG labeled by photografting with different ligands was included in PLGA-based 
nanoparticles of 200 nm [12]. The presence of the ligands on the PEG chain and at the surface of the 
nanoparticles was demonstrated by XPS [30]. The efficiency of ligand photografting was also assessed (3000-
5000 pmole per gram of polymer) [29]. Even though grafting of RGD on the nanoparticles has been shown to 
enhance their transport by M cells and elicit immune response after oral immunization [12], we hypothesised that 
using novel non-peptidic ligand would enhance the stability of the ligand in the gastro-intestinal tract and 
enhance the immune response after oral vaccination. 
To investigate the influence of the targeting moiety on their transport through the intestinal epithelium, in vitro 
studies performed on a model of the human FAE (co-cultures). RGD and RGDp increased nanoparticle transport 
by M cells. The specific targeting of the β1 integrins by the RGD- and RGDp-nanoparticles was demonstrated by 
the inhibition of their transport by anti-β1 integrin. Mannose was also able to increase the transport of 
nanoparticles by M cells compared to that of non-targeted nanoparticules. However, this ligand was not specific 
to M cells since the transport of man-nanoparticles was also improved by enterocytes. These results could be 
explained by the presence of a mannose receptor at the apical surface of human enterocytes. Although this 
receptor has been reported to be overexpressed in mouse FAE [35,36], we could not confirm its presence in our 
in vitro model (unpublished results). Mannose presence at the nanoparticle surface could modify their 
bioadhesion to the intestinal mucosa, promoting their uptake by enterocytes (mono-cultures), APC or DC 
inserted in the epithelium and M cells (co-cultures) [37,38]. This adhesive mechanism could be related to the 
high binding affinity of mannose residues to the mannose-binding lectins that are expressed on the lymphoid and 
non-lymphoid cells of the gut [39,40]. 
M cells are now considered as a major protagonist in the development of oral vaccine formulations, many efforts 
being focused on the improvement of the transcytosis of antigen-loaded nanoparticles by M cells. However, it is 
well known that APC such as DCs and macrophages also play an important role in the induction of the immune 
response after oral immunization. Mouse and human DCs and macrophages have been shown to express a 
mannose receptor, and this receptor has been exploited to deliver antigens, resulting in a more robust immune 
response [21-23,41]. Uptake studies by macrophages were carried out to investigate whether the labeling of 
nanoparticles with the different ligands can enhance the in vitro uptake of the nanoparticles by a mouse 
macrophage cell line. As expected [21 ], the uptake of mannose-labeled nanoparticles by macrophages was 
enhanced. The presence of ligand such as RGD, LDVd, and LDVp at the nanoparticle surface also increased 
their uptake by macrophages compared to non-targeted nanoparticles. 
Both intragastric and intraduodenal immunizations with ovalbumin-loaded nanoparticles effectively induced an 
immune response. However, this immune response and the number of responding mice were significantly 
increased after intraduodenal administration, when compared to the delivery by gavage. Specific anti-ovalbumin 
IgG was detected in the sera of some of the mice immunized by gavage, while all mice immunized by 
intramuscular produced specific IgG antibodies. The presence of non-responders in orally vaccinated mice has 
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been frequently reported in different studies [42-44]. Moreover, some immunization studies used high oral doses 
of encapsulated antigen and successive administrations to obtain significant immune responses in mice, even 
with potent immunogens such as BSA or ovalbumin [45,46]. Intragastric administration of LDVd-nanoparticles 
elicited in three out of eight mice a higher IgG titer than after IM injection of free ovalbumin. Moreover, LDVd- 
nanoparticles induced significant levels of IgG2a antibodies after intragastric administration compared to the 
absence of this isotype elicited by the IM injection and by the free oral peptide (data not shown). 
When nanoparticles were administered by the intraduodenal route, the immune response was significantly 
increased. The higher response induced by intraduodenal injection could be due to a higher concentration of 
local nanoparticles in the duodenum and/or no degradation by the harsh gastric environment and enzymes. The 
different ligands present at the nanoparticle surface increased the IgG response compared with non-targeted 
nanoparticles. RGDp, LDVd and mannose labeling of nanoparticles elicited a stronger immune response after 
intraduodenal administration with a higher production of IgG than after IM injection of non-adjuvanted 
ovalbumin. Although all groups except mice immunized with free ovalbumin elicited a mixed IgG1/IgG2a 
response, the IgG1 subclasses were predominantly expressed. However, the immune response was more 
balanced for the groups immunized with the nanoparticles when compared to mice immunized by IM. This is 
consistent with other reports stating that the major difference between the immune response elicited by 
conventional formulation and PLGA particles is the induction of a balanced Th1 and Th2 responses to PLGA 
particles compared to Th2 response to free OVA [47]. All the formulations were able to induce a cellular 
immune response, as shown by the IFN-γ production in splenocytes. However, some differences were observed 
in this IFN-γ production in function of the ligand grafted at the nanoparticle surface, suggesting a different 
process in the induction of the immune response, possibly due to a different recognition by the APC. 
The high immunization obtained after immunization with RGDp, LDVd and man-nanoparticles could be 
explained in part by the improved transport of those formulations by the M-like cells and/or by their better 
internalization by macrophages compared to other formulations. On the basis of results obtained in the present 
study, it is very difficult to determine whether the best strategy is to target the apical surface of M cells or to 
target the immune cells present in their basolateral pocket. Indeed, RGDp-nanoparticles showed increased 
transport in the in vitro model, but were poorly internalized by macrophages. On the contrary, LDVd-
nanoparticles were very weakly transported in vitro but their uptake by macrophage was high. Mannose-grafted 
nanoparticles were transported by enterocytes and M cells and internalized well by macrophages. In vivo, we 
demonstrated that the use of all of these ligands at the nanoparticle surface allowed an increase in the specific 
IgG production in the sera of mice after intraduodenal immunization, confirming the importance of targeting the 
carriers towards M cells or immune cells. The cellular immune response seen after intraduodenal administration 
indicates that a different immune response occurs with different ligands present on the surface of the 
nanoparticle. This could be attributed to the variations of uptake of these particles by M cells and/or APC, thus 
causing a change in the induction pathway. The comparison with data reported by other groups is difficult 
because antigen, dose, timing of priming and boost(s) as well as IgG titer definition widely differ. However, the 
presence of ligands such as vitamin B12 [48] or thiamine [34] has been shown to enhance immune response after 
oral delivery. 
The increased transmucosal uptake of vaccine particles via the targeting of M cells or of immune cells influenced 
the profile and the intensity of the immune response obtained after intraduodenal vaccination. Optimal oral 
vaccination effects with nanoparticle delivery systems should therefore be achieved with formulations having 
both M cell targeting molecules in addition to ligands of the APCs of the lymphoid tissue. The addition of a 
mucosal adjuvant in the formulation could also be considered. 
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